A New Molecular Mechanism For Colorectal Cancer: A New Target For Cancer Therapies
Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease. The research, published in the journal Gastroenterology1, also reveals how a technique called RNA interference can - by inactivating both genes - kill, in just 48 hours, as much as 80% of cancer cells.
Chronic Constipation - Three Presentations And Four Additional Posters Reinforce Efficacy And Safety Profile Of RESOLOR
Movetis NV, a European-based GI specialist pharmaceutical company, announces that it has presented substantial new data from different studies this week at the prestigious Digestive Disease Week (DDW) 2008 Congress.
Early Esophageal Cancer And Pre Cancer Eliminated With Non Surgical Treatment Combination
BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system.
Ironwood Pharmaceuticals And Forest Laboratories Announce Presentation Of Linaclotide Phase 2b Chronic Constipation Study Results
Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC).
New Approach To Treating Autoimmune Disease Developed By Weizmann Institute Scientists
In autoimmune diseases, the immune system turns against the body's own tissues and organs, wreaking havoc and destruction for no apparent reason. Partly because the origins of these diseases are so obscure, no effective treatment exists, and the suffering they inflict is enormous.
Merck Serono Receives CHMP Positive Opinion For Marketing Authorization For Erbitux Including 1st-Line Colorectal Cancer In The European Union
Merck KGaA announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), for its application to broaden the use of the targeted cancer therapy Erbitux (cetuximab) to an enlarged label, also including 1st-line treatment of metastatic colorectal cancer (mCRC) in patients with KRAS wild-type tumors.
Whole Milk Is Effective And Cost-Effective As Oral Contrast Agent
An item commonly found in many homes - whole milk - is just as effective, costs less and is easier on the patient than a diluted (0.1%) barium suspension that is also commonly used as an oral contrast agent in conjunction with CT to examine the gastrointestinal tract, a new study finds.
World Gastroenterology Organisation And Danone Launch Global Campaign To Improve Digestive Health
Today, on the occasion of World Digestive Health Day (WDHD), the World Gastroenterology Organisation (WGO) has launched a year-long campaign titled 'Optimum Health and Nutrition' focusing on the link between nutrition and digestive health. An unbalanced diet, rushing or skipping food and an unhealthy lifestyle may all contribute to digestive disorders (such as constipation, bloating and heartburn ) which affect millions worldwide.
Study Finds Flat Carbonated Beverages Ineffective For Hydration
An article published in the May issue of Archives of Diseasein Childhoodadvises that children with acute vomiting and diarrhea should not use'flat' carbonated beverages as an alternative for oral rehydrationsolution.
New England Journal Of Medicine Publishes Results From A RELISTOR Phase 3 Clinical Study
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the publication of results from a pivotal phase 3 trial of RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection in the May 29, 2008 issue of the New England Journal of Medicine.